Impact of baseline and newly acquired conduction disorders on need for permanent pacemakers with 3 consecutive generations of self-expanding transcatheter aortic heart valves

Herbert G. Kroon, Lennart van Gils, Francesca Ziviello, Maarten van Wiechen, Joris Ooms, Zouhair Rahhab, Nahid El Faquir, Anne-Marie Maugenest, Isabella Kardys, Joost Daemen, Peter P. de Jaegere, Nicolas M. Van Mieghem*

Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands

1. Introduction

Recently, studies have confirmed non-inferiority of transcatheter aortic valve replacement (TAVR) in patients at low risk for surgery [1,2]. Still, conduction abnormalities and need for permanent pacemaker implantation (PPI) remain frequent after TAVR because of device protrusion into the left ventricular outflow tract and consequent pressure onto the atrioventricular (AV) node and His bundle [3,4]. PPI is more frequent with the self-expanding compared to balloon-expandable transcatheter heart valve (THV) [5]. The 2nd generation Evolut R THV (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8]. The 3rd generation Evolut PRO (Medtronic Inc., Minneapolis, USA) introduced partial recapturability and repositionability to optimize implantation depth and limit paravalvular leakage and need for PPI and three consecutive studies reported <20% PPI rates in their initial clinical experience with Evolut R THV [6,7,8].

Abbreviations: TAVR, Transcatheter aortic valve replacement; PPI, Permanent pacemaker implantation; THV, Transcatheter heart valve; ECG, Electrocardiogram; SFV, Self-expanding valve; AV, Atrioventricular; STS, Society of Thoracic Surgeons; AVB, 1st degree atrioventricular block; LBBB, Left bundle branch block; RBBB, Right bundle branch block; LVOT, Left ventricular outflow tract; AF, Atrial fibrillation.

* Corresponding author at: Department of Interventional Cardiology, Thoraxcenter, ErasmusMC, Room N-645, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
E-mail address: n.vanmieghem@erasmusmc.nl (N.M. Van Mieghem).

© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
in newer generations of self-expanding valves (SEV’s). In this study we aimed to compare conduction dynamics and need for PPI after TAVR among 3 consecutive generations of self-expanding THV’s.

2. Methods

All consecutive patients who underwent transfemoral or transsubclavian TAVR with 3 generations of self-expanding THV’s for severe aortic valve stenosis (AS) between January 2012 and December 2018 in our center were entered in a dedicated prospective database. All patients provided written informed consent for the TAVR procedure and subsequent data analysis for research purposes. This present study was complementary with the Declaration of Helsinki and approved by the Erasmus University Medical Center Rotterdam Institutional Review Board. Patients with a pacemaker at baseline, who died within 72 h post TAVR or who had no electrocardiogram (ECG) data during their admission were excluded from the analysis.

2.1. Electrocardiogram analysis and conduction dynamics

The methodology of ECG analysis has been previously described in detail [13]. In short, twelve-lead electrocardiograms were collected at baseline the day before TAVR and daily afterwards up to discharge, as well as at the one-month follow-up visit in the outpatient clinic. Patients were stratified based on conduction at baseline into Cohort A with normal conduction and Cohort B with any conduction abnormality (any degree AV-block, fascicular block or complete bundle branch block). Dedicated clinical researchers (HK, LVG) analyzed all ECGs and an experienced interventional cardiologist (NVM) was consulted in case of discrepancy. Only ECGs without temporary pacemaker intrusion were analyzed for rhythm, conduction times, and the presence of atioventricular block or bundle branch block. We analyzed the ECG with the longest QRS-duration, when multiple ECG’s were present.

Conduction dynamics after TAVR were divided into three QRS-patterns, as previously described by our group [13]:

1. Stable QRS-pattern: QRS-prolongation after TAVR ≤ 20 ms OR more than 20 ms but never exceeding a total QRS-duration of 120 ms throughout the admission.
2. Transient QRS-prolongation: QRS-prolongation > 20 ms post-TAVR, but recovery within 20 ms before discharge.
3. Persistent QRS-prolongation: QRS-prolongation > 20 ms after TAVR which persisted at least up to discharge.

Patients who developed a new bundle branch block after TAVR were specifically classified as transient or persistent QRS-prolongation depending on whether it resolved before discharge or not.

2.2. Outcomes

The primary outcome for this study was the need for PPI. The requirement for a permanent pacemaker was per treating physician’s decision and in compliance with the European Society of Cardiology guidelines on cardiac pacing and cardiac resynchronization therapy.

2.3. Data analysis

Continuous variables were presented as mean (±SD) or median (interquartile range) and categorical variables as n (%). The distribution of continuous variables was examined for normality through histograms and Q-Q plots. To compare continuous variables between the three different transcatheter heart valve designs one-way ANOVA and the non-parametric Kruskal-Wallis test was performed, according to the distribution of the variables. For categorical variables the Pearson χ² test or the Fisher exact test as appropriate was performed. For ensuing pairwise comparisons, the Bonferroni correction was used to account for multiple testing. Cumulative pacemaker-free survival analysis was performed using the Kaplan-Meier method, with date of the TAVR procedure as initial time of follow-up (t = 0). A log-rank test was applied to compare between-group differences. Additionally, we performed multivariable logistic regression to estimate the effect of the three separate THV’s on need for PPI at 30 days after TAVR. In this analysis we entered THV type and added baseline covariates, based on selection of those covariates that displayed a difference with a p-value less than 0.10 in univariate analysis. When limited number of events were present we chose those covariates that had a p-value less than 0.10 and are known risk factors for need for permanent pacemaker (i.e. male gender, depth of implantation, RBBB at baseline). All statistical analyses were performed with SPSS version 24.0 (IBM Corporation, New York, United States of America). A two-sided value of p < 0.05 was considered statistically significant.

3. Results

A total of 362 (54% male) patients who underwent TAVR with CoreValve (N = 113), Evolut R (N = 157) or Evolut PRO (N = 92) THV-design were included in the analysis after exclusion of cases with an alternative access approach (Direct Aortic, N = 1), mortality within 72 h after the index procedure (N = 5), a pacemaker at baseline (N = 37) or missing ECG data (N = 1). The overall median age and Society of Thoracic Surgeons (STS) predicted risk of mortality were 80 [73–84] years and 4.2% [2.8–6.3], respectively. TAVR was performed through the transfemoral route in the majority (90%) of cases. All baseline characteristics are displayed in Table 1. Half of all patients (59%) had no conduction disturbances at baseline (Cohort A), while the remainder presented with some kind of conduction abnormality, most frequently a 1st degree atioventricular block (AV1B, 74/362, 20%) or a left bundle branch block (LBBB, 35/362, 10%) as displayed in Supplementary Table 1.

3.1. Conduction dynamics with the three consecutive generations of SEV’s regardless of baseline conduction

Patients who underwent TAVR with Evolut R or PRO were treated more often through a transfemoral route (CoreValve 84% vs. Evolut R 89% vs. Evolut PRO 97%, P = 0.001, Table 1). Implantation depth was similar for the 3 different THVs (7.1 ± 3.2 mm vs. 7.0 ± 3.3 mm vs. 7.2 ± 2.6 mm, P = 0.87). Predilatation occurred more often with CoreValve (80% vs. 8% vs. 12%), but post-dilatation less (28% vs. 42% vs. 41%). No significant differences were observed in prevalence of (functional) bicuspid valves and calcification level in the left ventricular out flow tract (LVOT) or annulus. Patients who underwent TAVR with CoreValve had more often a LBBB at baseline (16% vs. 7% vs. 7%, P = 0.03), but presence of right bundle branch block (RBBB) was similar between three valves. The occurrence of new conduction disturbances during the index procedure did not differ significantly between the three self-expanding valves. However, thereafter new onset atrial fibrillation (AF) appeared more frequent with CoreValve (14% vs. 5% vs. 3%, P = 0.004) and new permanent RBBB was more frequent with Evolut PRO (0% vs. 1% vs. 7%, P = 0.001). Need for PPI tended to occur more often with CoreValve (27% vs. 17% vs. 19%, P = 0.08, Table 2). Importantly, only three patients who underwent CoreValve TAVR with a LBBB at baseline were in need for PPI. Kaplan Meier curves for the pacemaker-free survival probability for the three transcatheter heart valves are displayed in Supplementary Fig. 1 (Log-Rank test P = 0.073). In multivariable logistic regression analysis the use of Evolut R (OR 0.38, 95% CI 0.19–0.78, P = 0.008) and PRO (OR 0.41, 95% CI 0.19–0.91, P-value = 0.028) were independently associated with less need for PPI, also when corrected for depth of implantation, conduction disturbances at baseline and male gender (Table 3). Univariate analysis is displayed in Supplementary Table 2. Prevalence of the three predefined conduction patterns did not differ between the three THV-designs. However, CoreValve patients with persistent
QRS-prolongation required a permanent pacemaker twice as often compared to the others (50% vs. 24% vs. 23%, P = 0.006).

### 3.2. Conduction dynamics between the THV-designs in Cohort A

In patients with normal conduction at baseline patient demographics were comparable between the three THV-designs (N = 214, Supplementary Table 3). Patients treated with CoreValve were more often male (53% vs. 48% vs. 30%, P = 0.03), had higher creatinine levels (97 vs. 91 vs. 81 umol/L, P = 0.03) and more often underwent pre-dilatation before valve deployment (80% vs. 8% vs. 14%, P = 0.0005). The appearance of per-procedural conduction disturbances did not differ significantly, while new permanent RBBB occurred more often with Evolut PRO compared to CoreValve and Evolut R (9% vs. 0% vs. 1%, P = 0.005). Implantation of CoreValve resulted in higher rates of PPI compared to Evolut R and PRO (25% vs. 6% vs. 11%, P = 0.002). The stable QRS-pattern was most frequently associated with Evolut R (CoreValve 30% vs. Evolut R 42% vs. Evolut PRO 21%, P = 0.029). The different conduction patterns correlated highly with the need for PPI in patients with normal baseline conduction. Only patients with persistent QRS-prolongation required PPI in cohort A, but less frequent with Evolut R and PRO (50% vs. 13% vs. 17%, P = 0.001, Fig. 1). Of note, one patient with stable QRS-duration needed a permanent pacemaker after discharge, when she was brought in the emergency room with hyperkalemia and this was not considered as a QRS-pattern-related pacemaker. In patients with transient QRS-prolongation the QRS-width reached its maximum the same day of the procedure in 60% of patients, the next day in 73% and the 2nd day in 78% of patients, cumulatively. All patients with transient prolongation reached their maximum QRS-prolongation within 6 days after TAVR.
3.3. Conduction dynamics between the THV-designs in Cohort B

Patients with abnormal conduction at baseline who underwent TAVR with CoreValve had more pre-dilatation (79% vs. 7% vs. 8%, P < 0.001) and less often transfemoral access (79% vs. 88% vs. 97%, P = 0.04). No significant differences with regards to baseline conduction abnormalities, prevalence of (functional) bicuspid valves and LVOT/annular calcifications were observed. Also, the occurrence of per-procedural conduction disturbances between the three self-expanding THVs were similar. Patients with CoreValve more often developed atrial fibrillation after TAVR compared to those treated with Evolut PRO. An equal number of patients required PPI (≈30% with all THV-designs, P = 0.90, Supplementary Table 4) in Cohort B. Median recovery of transient QRS-prolongation was within 24 h post TAVR in all groups. Conduction patterns did not predict need for PPI with all three THV’s in Cohort B (Fig. 2).

4. Discussion

Our study demonstrates that Evolut R and PRO are associated with less need for PPI compared to CoreValve, particularly in patients with normal conduction at baseline. Baseline conduction status and changing QRS-patterns after TAVR have implications for a permanent pacemaker. No PPI is required when QRS-width is normal at baseline and not
permanently affected after TAVR. Patients with normal baseline conduction and acquired permanent conduction abnormalities are at risk for PPI, more so after Corevalve.

4.1. Conduction dynamics in perspective of conduction status at baseline

Overall, Evolut R and PRO were associated with a tendency towards less PPI compared to Corevalve (17% vs. 19% vs. 27%, P = 0.08). These lower pacemaker rates of 17% and 19% are comparable with numbers currently reported in the literature for the newest generations of Medtronic SEV’s. Pacemaker rates vary from 12 to 20% for the Evolut R and PRO and 25–30% with CoreValve [8–11,14–17]. Also, in multivariable logistic regression analysis Evolut R and PRO seemed associated with less need for PPI compared to CoreValve, when correcting for depth of implantation, male gender and baseline conduction abnormalities. The most important finding in this analysis is that patients without baseline conduction disturbances and no newly acquired persistent QRS-prolongation never needed a PPI regardless of the generation of self-expanding THV. Previous studies mainly reported on the impact of baseline variables to predict PPI post-TAVR like gender, baseline conduction status and THV-design [3–7]. We correlated baseline conduction status to periprocedural conduction dynamics in predicting the risk of PPI after TAVR. Also, Toggweiler et al. reported the predictive value of the ECG after TAVR and suggested that patients with no conduction disturbances post-TAVR never required PPI [12]. Patients who developed a conduction disorder required extensive monitoring until the 12 lead ECG was stable for 48 h after the index procedure [12]. We refined this notion by adding dynamic QRS-patterns post-TAVR to predict the need for PPI. Our findings may further elaborate on prior conclusions because patients without baseline conduction abnormalities and no or transient acquired QRS-prolongation never needed PPI. Only patients with newly acquired persistent conduction disorders were at risk for a pacemaker. Those findings are in line with the recent study conducted by our group in 300 patients treated with self-expanding (1st generation), balloon expandable and mechanically expanded THVs [13]. Similarly, patients with normal conduction at baseline and no newly acquired persistent QRS-prolongation never required PPI.

The present study reinforces the importance of baseline conduction status and peri-procedural conduction dynamics in predicting the need for PPI with exclusively SEV THVs.

TAVR with Evolut R and PRO in patients with no conduction disturbances at baseline resulted in lower pacemaker rates (6% and 11%) as compared to 25% with Corevalve. For all THV-designs the QRS-patterns predicted the need for PPI in patients with normal conduction at baseline. Patients were at risk for PPI if they acquired a persistent QRS-prolongation. Of note, persistent prolongation could be distinguished from transient prolongation within 1 day post-TAVR in approximately three-quarters of patients. In early TAVR experience there was a relationship between the occurrence of conduction disorders and balloon pre-dilation [18]. However, it remains questionable whether less pre-dilatation in patients treated with the latest generations SEV’s could explain the lower PPI rate. Conversely, post-dilatation was performed more frequently with the newer generations compared to CoreValve. Also, in our study population, pre- and post-dilatation were not associated with need for PPI.

Evolut R introduced partial repositionability and recapturability to optimize valve deployment and implantation depth [19]. Of note we did not find different implantation depths with the 3 THV designs. Evolut R also featured a more consistent and homogeneous distribution of the radial force which together with the redesigned inflow portion may have less impact pressure on the left ventricular outflow tract [19]. Its successor, the 3rd generation Evolut PRO was built on the same principles and added an outer pericardial wrap to minimize paravalvular leakage. Subsequent device iterations, increased TAVR experience, a trend for treating patients at lower risk for surgery and procedure modifications may have increased overall safety as well.

Decision making regarding PPI after TAVR may have changed over time. Still, high grade atrioventricular blocks remained the principle indication for PPI with all three valve types. Our findings may help identify patients with SEV TAVR who could be eligible for safe early discharge without the risk for (late) conduction disorders and need for PPI provided there was normal conduction at baseline. The QRS-patterns did not correlate with need for PPI in patients with baseline conduction abnormalities. Those patients therefore require telemetry monitoring for a longer time to rule out progression to potentially lethal high-grade atrioventricular block.

4.2. Study limitations

This was a single-center, observational study with inherent time bias. Growing TAVR experience among operators and treating physicians may have affected conduction dynamics (through mature implantation technique) and refined decision making related to permanent pacemakers. Over time the relative proportion of alternative (non-transfemoral) access and balloon valvuloplasty prior to TAVR declined. The non-randomized, observational aspect of this study including the implantation of the THV’s in different time periods preclude any definite conclusions. Our findings should be interpreted as hypothesis generating. Although decision for a permanent pacemaker was at the treating physician’s discretion, indications consisted predominantly of high degree atrioventricular block and thus were according to the current European Society of Cardiology guidelines on cardiac pacing. At our center the temporary pacemaker is left in situ less than 1 day after the procedure. A permanent pacemaker was implanted when a patient was pacemaker dependent 24 h after the index procedure. This may have prevented resolution of conduction disorders before the decision to proceed with PPI. Overall, analyzable ECG’s (without pacemaker interference) were present for 68% of total hospitalized days at our center and referral centers. Percentage of missing ECGs was lower with the newer Evolut R and PRO valve, which may have resulted in underestimation of the prevalence of high degree atrioventricular block in the CoreValve cohort. Incompleteness of present ECG’s reflects the retrospective analysis of current clinical practice, however missing ECG’s were equally distributed between our three predefined conduction patterns. Therefore we think that our predefined conduction patterns are valid. Our study with daily ECG’s after TAVR represents one of the most extensive samples of conduction times reported to date.

5. Conclusion

Newer generation Evolut R and PRO were associated with less PPI than Corevalve in present study. Acquired persistent QRS-prolongation predicted PPI after TAVR only in patients with normal conduction at baseline, and this finding was valid regardless of the generation of SEV that was used. Our findings may help identify eligible patients for early discharge after Evolut R/PRO TAVR.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.carrev.2021.01.025.

Funding or grants

None.

CRediT authorship contribution statement

Herbert G. Kroon: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft. Lennart van Gils: Conceptualization, Methodology, Investigation, Writing – review & editing. Francesca Ziviello: Conceptualization, Investigation, Methodology, Writing – review & editing. Maarten van Wiechen: Conceptualization, Investigation, Methodology, Writing –
Declaration of competing interest

HK: no conflicts of interest to declare.
LGV: no conflicts of interest to declare.
MVW: no conflicts of interest to declare.
JO: no conflicts of interest to declare.
FZ: no conflicts of interest to declare.
ZR: no conflicts of interest to declare.
NEF: no conflicts of interest to declare.
AM: no conflicts of interest to declare.
IK: no conflicts of interest to declare.
JD: no conflicts of interest to declare.
PDJ: is proctor for Boston Scientific.

NVM has received research grants from Medtronic, Boston scientific, Edwards Lifesciences, Abbott, PulseCath. He is advisor to PulseCath, Ancora, Boston Scientific, Medtronic.

Acknowledgements

None.

References

[1] Popma JJ, Deeb GM, Yakubov SJ, Munntaz M, Gada H, O’Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–15.

[2] Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–705.

[3] Nijenhuis VJ, Van Dijk VT, Chaldoupi SM, Balt JC, Ten Berg JM. Severe conduction defects requiring permanent pacemaker implantation in patients with a new-onset left bundle branch block after transcatheter aortic valve implantation. Europractice. 2017;19(6):1015–21.

[4] van der Boon RM, Nuijs RJ, Van Mieghem NM, Jordaens L, Rodes-Cabau J, van Domburg RT, et al. New conduction abnormalities after TAVI-frequency and causes. Nat Rev Cardiol. 2012;9(8):454–63.

[5] Siontis GC, Juni P, Pilgrim T, Stortecky S, Bullesfeld I, Meier B, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64(2):129–40.

[6] Khawaja MZ, Rajani R, Cook A, Khavandi A, Maynagh A, Chowdhary S, et al. Permanent pacemaker insertion after CoreValve transcatheter aortic valve implantation: incidence and contributing factors (the UK CoreValve collaborative). Circulation. 2011;123(9):951–60.

[7] Nazif TM, Dizon JM, Hahn RT, Xu K, Rahalarios V, Douglas PS, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscatheterER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8(1 Pt A):60–9.

[8] Popma JJ, Reardon MJ, Khubaz K, Harrison JK, Hughes GC, Kodali S, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the Evolut R U.S. study. JACC Cardiovasc Interv. 2017;10(3):268–75.

[9] Kala SS, Firoozi S, Yeh J, Blackman DJ, Rashid S, Davies S, et al. Initial experience of a second-generation self-expanding transcatheter aortic valve: the UK & Ireland Evolut R Implanters’ registry. JACC Cardiovasc Interv. 2017;10(3):276–82.

[10] Grube E, Van Mieghem NM, Bleiziffer S, Modine T, Bosmans J, Manoharan G, et al. Clinical outcomes with a repositionable self-expanding transcatheter aortic valve prosthesis: the international FORWARD study. J Am Coll Cardiol. 2017;70(7):845–53.

[11] Forrest JK, Mangi AA, Popma JJ, Khubaz K, Reardon MJ, Kleiman NS, et al. Early outcomes with the Evolut PR repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv. 2018;11(2):160–8.

[12] Toggweiler S, Stortecky S, Holy E, Zuik K, Cucali F, Nitschphach F, et al. The electrocardiogram after transcatheter aortic valve replacement determines the risk for post-procedural high-degree AV block and the need for telemetry monitoring. JACC Cardiovasc Interv. 2016;9(12):1289–76.

[13] van Gil L, Baart S, Kroon H, Rahhab Z, El Faquir N, Rodrigo Oliveira R, et al. Conduction dynamics after transcatheter aortic valve implantation and implications for permanent pacemaker implantation and early discharge: the CONDUCT-study. Europace. 2018;20(12):1981–6.

[14] Hellhammer K, Piayda K, Azizi S, Kleinhecht L, Makosch M, Hennig L, et al. The latest evolution of the medtronic corevalve system in the era of transcatheter aortic valve replacement: matched comparison of the Evolut PRO and Evolut R. JACC Cardiovasc Interv. 2018;11(22):2314–22.

[15] Pagnesi M, Kim WK, Consoli L, Barbanti M, Stefanini GG, Zeus T, et al. Transcatheter aortic valve replacement with next-generation self-expanding devices: a multicenter, retrospective, propensity-matched comparison of Evolut PRO versus Acurate neo transcatheter heart valves. JACC Cardiovasc Interv. 2019;12(5):433–43.

[16] Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790–8.

[17] Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the Evolut PRO U.S. study. JACC Cardiovasc Interv. 2014;7(10):1025–32.

[18] Nuis RJ, Van Mieghem NM, Schultz CJ, Taikas A, Van der Boon RM, Maugenest AM, et al. Timing and potential mechanisms of new conduction abnormalities during the implantation of the Medtronic CoreValve system in patients with aortic stenosis. Eur Heart J. 2011;32(16):2067–74.

[19] Piazza M, Martucci G, Lachapelle K, de Varennes B, Bilodeau L, Buithieu J, et al. First-in-human experience with the Medtronic CoreValve Evolut R EuroIntervention. 2014;9(11):1260–3.